News
- Author:
- Neil Osterweil
Publish date: June 4, 2020
Neither disease-free survival nor overall survival were improved by adding celecoxib to adjuvant FOLFOX chemotherapy.
News
- Author:
- Neil Osterweil
Publish date: June 3, 2020
Cytoreductive surgery provided a significant survival benefit over chemotherapy alone for patients with favorable presurgical predictive scores.
News
- Author:
- Neil Osterweil
Publish date: June 1, 2020
Treating an intact primary tumor did not improve overall survival in women with de novo metastatic breast cancer ...
News
- Author:
- Neil Osterweil
Publish date: May 30, 2020
Compared with leuprolide, relugolix reduced testosterone levels more rapidly and was associated with a lower incidence of cardiovascular side effec...
News
- Author:
- Neil Osterweil
Publish date: May 29, 2020
Pembrolizumab outperformed chemotherapy in patients with microsatellite-instability high/mismatch repair-deficient metastatic colorectal cancer.
News
- Author:
- Neil Osterweil
Publish date: May 29, 2020
Patients with triple-negative breast cancers with PD-L1 combined positive score higher than 10 had better progression-free survival with pembrolizu...
News
- Author:
- Neil Osterweil
Publish date: May 28, 2020
Osimertinib reduced the risk of disease recurrence or death by 79% in patients with EGFR-mutated non–small cell lung cancer.
News
- Author:
- Neil Osterweil
Publish date: May 28, 2020
Cancer in progression and treatment with hydroxychloroquine plus azithromycin were associated with an increased r...
News
- Author:
- Neil Osterweil
Publish date: May 12, 2020
One MEK inhibitor, trametinib, bested standard care, but another MEK inhibitor, binimetinib, did not.
News
- Author:
- Neil Osterweil
Publish date: May 11, 2020
Time to viral negativity and hospital stay were shorter for those treated with lopinavir/ritonavir, ribavirin, an...
News
- Author:
- Neil Osterweil
Publish date: May 6, 2020
Higher mortality risk among whites with severe COVID-19 infections may be linked to higher propensity for th...
News
- Author:
- Neil Osterweil
Publish date: May 1, 2020
Combining the immune activator Imprime PGG with pembrolizumab may improve survival in patients with metastatic tr...
News
- Author:
- Neil Osterweil
Publish date: April 29, 2020
There was no improvement in overall survival when atezolizumab was added to enzalutamide in patients with metasta...
News
- Author:
- Neil Osterweil
Publish date: April 29, 2020
Adding durvalumab and olaparib to standard neoadjuvant chemotherapy increased rates of pathologic complete respon...
Article
- Author:
- Neil Osterweil
Publish date: April 27, 2020
Oncologists worry about patients missing essential screening, diagnosis, or treatment, and the interruption of im...
